Breast DCIS
Understanding Breast DCIS diagnosis, coding, and documentation? Learn about Ductal Carcinoma In Situ, also known as non-invasive breast cancer. This resource provides information on clinical terms, healthcare guidelines, and medical coding for Breast DCIS for accurate documentation and patient care. Find details on diagnosis, staging, and treatment options for DCIS.
Non-invasive breast cancer confined to milk ducts, not yet spread to surrounding tissue.
Often no symptoms. May present as breast lump, nipple discharge, or mammogram abnormality.
Detected during routine mammogram screening or breast self-exam.
ICD-10 Code Families
Complete code families applicable to D05.10
When to use each related code
| Description | When to use |
|---|---|
| Non-invasive breast cancer cells within milk ducts. | Use for DCIS confined to ducts. Code stage and grade if documented. |
| Invasive breast cancer spread beyond milk ducts. | Use for invasive breast cancer. Code histological type, grade, and stage. |
| Abnormal breast cells with increased risk of cancer. | Use for atypical hyperplasia (ductal or lobular) not diagnosed as DCIS or invasive cancer. |
Best-practice checklist
- ✓Document DCIS grade (e.g., low, intermediate, high).
- ✓Laterality (right, left, bilateral) required.
- ✓Record DCIS nuclear grade.
- ✓Document necrosis (comedo or non-comedo).
- ✓Include margin status if excised.
Common pitfalls to avoid
Missing or incorrect laterality (right, left, bilateral) can impact treatment and staging data accuracy, leading to reimbursement issues.
Incomplete documentation of DCIS subtype (e.g., comedo, cribriform) may affect accurate coding and subsequent treatment planning.
Insufficient documentation differentiating DCIS from invasive ductal carcinoma (IDC) can lead to miscoding and incorrect treatment protocols.
Best-practice tips
- 01Accurate ICD-10 coding: D05.* for DCIS, ensuring proper subtype documentation.
- 02Detailed clinical notes: Tumor size, grade, ER/PR/HER2 status for optimal CDI.
- 03Timely follow-up scheduling: Adherence to NCCN guidelines for surveillance or treatment.
- 04Multidisciplinary review: Pathology, radiology, oncology input for best treatment plan.
- 05Patient education: Clear communication about DCIS diagnosis, treatment options, and risks.
Step-by-step checklist
- 1
Verify histology confirms DCIS (ICD-10 D05.0)
- 2
Confirm imaging findings correlate with DCIS diagnosis
- 3
Assess margin status for complete excision documentation
- 4
Evaluate patient risk factors for recurrence (age, family history)
- 5
Discuss treatment options per guidelines (NCCN, ASCO)
Ready-to-paste narrative
Patient presents with concerns regarding breast changes. The patient reports [mention specific symptom, e.g., no palpable lump, but an abnormal mammogram finding]. Mammography reveals [describe mammographic findings, e.g., microcalcifications in the upper outer quadrant of the left breast]. Subsequent biopsy confirms a diagnosis of ductal carcinoma in situ (DCIS), also known as non-invasive breast cancer or stage 0 breast cancer. The DCIS is [specify grade, e.g., high-grade] and [specify nuclear grade, e.g., with comedonecrosis]. Immunohistochemical staining results are [describe ER, PR, and HER2 status]. Surgical options, including lumpectomy with sentinel node biopsy and mastectomy, were discussed with the patient. The risks and benefits of breast conserving surgery versus mastectomy, including the potential need for adjuvant radiation therapy, were thoroughly explained. The patient's decision regarding surgical management will be documented in a subsequent note. Differential diagnoses considered included atypical ductal hyperplasia and invasive ductal carcinoma. ICD-10 code D05.9 is documented for breast DCIS, unspecified. Patient education was provided regarding breast cancer screening, DCIS prognosis, and follow-up care. The patient will schedule a follow-up appointment to discuss the surgical plan and address any further questions.
Common questions and answers
What are the most effective surgical management strategies for low-grade DCIS with microcalcifications detected on mammography in premenopausal women?+
Surgical management of low-grade ductal carcinoma in situ (DCIS) with microcalcifications in premenopausal women typically involves either breast-conserving surgery (lumpectomy) with radiation therapy or mastectomy. The choice depends on factors like the extent of DCIS, multifocality, patient preference, and family history. For small, low-grade, unifocal lesions, lumpectomy with radiation is often sufficient. However, mastectomy may be considered if achieving negative margins is challenging or if the patient has a strong family history of breast cancer. Sentinel node biopsy is generally not indicated for pure DCIS. Explore how oncotype DX testing can help personalize treatment decisions in certain DCIS cases. Consider implementing a risk-stratified approach to surveillance based on clinicopathologic features and patient preferences.
How can I differentiate DCIS from invasive breast cancer on imaging and biopsy, and what are the key pathological features that distinguish these diagnoses?+
Differentiating ductal carcinoma in situ (DCIS) from invasive breast cancer requires careful evaluation of both imaging and pathology findings. On mammography, DCIS often presents as microcalcifications, while invasive breast cancer may appear as a mass or architectural distortion. Ultrasound may show a mass or ductal changes for both. Biopsy is crucial for definitive diagnosis. Histologically, DCIS is characterized by the proliferation of malignant cells confined within the breast ducts, without invasion of the basement membrane. Invasive breast cancer, on the other hand, demonstrates stromal invasion by malignant cells. Key pathological features distinguishing DCIS include comedonecrosis, nuclear grade, and architectural pattern (e.g., cribriform, micropapillary, solid). Learn more about the specific immunohistochemical markers that can be used to further refine the diagnosis and prognosticate DCIS. Consider implementing a multidisciplinary approach to diagnosis involving radiologists, pathologists, and surgeons.
What are the current guidelines for post-surgical surveillance and follow-up for patients diagnosed with DCIS treated with breast-conserving surgery and radiation?+
Post-surgical surveillance for patients diagnosed with DCIS treated with breast-conserving surgery and radiation typically involves annual mammograms of the treated and contralateral breast. Clinical breast exams are recommended every 6-12 months for the first five years, then annually. The use of breast MRI for surveillance is generally not recommended for routine follow-up after DCIS treatment but may be considered in high-risk cases. Patients should be educated on breast self-awareness and encouraged to report any new changes or concerns. Explore the role of adjuvant endocrine therapy (e.g., tamoxifen, aromatase inhibitors) in reducing the risk of recurrence in hormone receptor-positive DCIS. Learn more about the long-term risks and benefits of different surveillance strategies for DCIS. Consider implementing patient-centered shared decision-making regarding follow-up care.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.